Table 1. Demographics and baseline clinical characteristics.
| Characteristics | Niraparib 300 mg (n=20) | |
|---|---|---|
| Age (yr) | 62.0 (47.0–85.0) | |
| Weight (kg) | 54.5 (36.4–80.2) | |
| <58 | 14 (70.0) | |
| ≥58, <77 | 5 (25.0) | |
| ≥77 | 1 (5.0) | |
| Mean±standard deviation | 53.7±9.7 | |
| Primary tumor site | ||
| Ovarian | 13 (65.0) | |
| Primary peritoneal | 5 (25.0) | |
| Fallopian tube | 2 (10.0) | |
| ECOG status | ||
| 0 | 15 (75.0) | |
| 1 | 5 (25.0) | |
| Tumor BRCA1/2 mutation status | ||
| Negative | 6 (30.0) | |
| Positive | 13 (65.0) | |
| Unknown | 1 (5.0) | |
| Cancer stage (FIGO) at initial diagnosis | ||
| IA | 1 (5.0) | |
| IC | 1 (5.0) | |
| IIB | 1 (5.0) | |
| IIC | 1 (5.0) | |
| IIIA | 1 (5.0) | |
| IIIC | 12 (60.0) | |
| IV | 3 (15.0) | |
| Number of previous chemotherapy lines | ||
| 3 | 12 (60.0) | |
| 4 | 8 (40.0) | |
| Type of previous chemotherapy | ||
| Taxane | 20 (100.0) | |
| Bevacizumab | 10 (50.0) | |
| Doxorubicin | 9 (45.0) | |
| Gemcitabine | 11 (55.0) | |
| Liposomal doxorubicin | 0 | |
| Best response to most recent platinum therapy | ||
| CR | 9 (45.0) | |
| PR | 8 (40.0) | |
| SD | 2 (10.0) | |
| Unknown | 1 (5.0) | |
Values are presented as median (min–max) or number (%) unless otherwise indicated. Table adapted from Okamoto et al. [11].
CR, complete response; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; PR, partial response; SD, stable disease.